Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Ramasamy K, Vij R, Kuter D, Cella D, Durie BGM, Abonour R, Rifkin RM, Ailawadhi S, Lee HC, Cowan AJ, Ho C, Dhanasiri S, Fish S, Yu E, Dhamane AD, Fang J, Marshall TS, Samuel A, Liu L, Katz J, Gu T, Jagannath S. Ramasamy K, et al. Clin Lymphoma Myeloma Leuk. 2024 Dec 6:S2152-2650(24)02441-8. doi: 10.1016/j.clml.2024.12.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39799046 Free article.
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner LI, Jagannath S. Lee HC, et al. Among authors: ramasamy k. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):112-122. doi: 10.1016/j.clml.2022.11.008. Epub 2022 Nov 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36567211 Free article.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Lee HC, et al. Among authors: ramasamy k. Eur J Haematol. 2024 Aug;113(2):190-200. doi: 10.1111/ejh.14214. Epub 2024 Apr 23. Eur J Haematol. 2024. PMID: 38654611
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Maouche N, Kishore B, Jenner MW, Boyd K, Bhatti Z, Bird SA, Chander G, Robinson R, Vallance GD, Offer M, Kothari J, Peniket A, Aitchison R, Dungarwalla M, Collings F, Bygrave C, Ramasamy K. Maouche N, et al. Among authors: ramasamy k. Leuk Lymphoma. 2021 Jun;62(6):1396-1404. doi: 10.1080/10428194.2020.1864355. Epub 2020 Dec 25. Leuk Lymphoma. 2021. PMID: 33356703
Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.
Sharpley FA, Djebbari F, Fourali S, Kothari J, Lynes JA, McLain-Smith S, Ramasamy K. Sharpley FA, et al. Among authors: ramasamy k. Leuk Lymphoma. 2020 Mar;61(3):732-736. doi: 10.1080/10428194.2019.1683737. Epub 2019 Nov 27. Leuk Lymphoma. 2020. PMID: 31771382 Free article. No abstract available.
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA. Sudha P, et al. Among authors: ramasamy k. Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695. Clin Cancer Res. 2022. PMID: 35522533 Free PMC article.
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
Ludwig H, Ramasamy K, Mateos MV, Kishore B, Gergely V, Ladicka M, Ori A, Simoni L, Bent-Ennakhil N, Stull DM, Gavini F, Terpos E, Hájek R. Ludwig H, et al. Among authors: ramasamy k. Clin Lymphoma Myeloma Leuk. 2024 Feb;24(2):e40-e49.e3. doi: 10.1016/j.clml.2023.10.003. Epub 2023 Oct 14. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37996265 Free article.
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. Terpos E, et al. Among authors: ramasamy k. Blood Cancer J. 2021 Feb 18;11(2):40. doi: 10.1038/s41408-021-00432-4. Blood Cancer J. 2021. PMID: 33602913 Free PMC article. Review.
585 results